NHS England has launched the first-ever gonorrhoea vaccine, aiming to curb the highest infection rates since 1918. The vaccine, adapted from the meningitis B jab, offers 30–40% efficacy and is initially available to high-risk groups.

With over 85,000 gonorrhoea cases reported in 2023, the vaccine rollout seeks to prevent 100,000 infections and save the NHS nearly £8 million over the next decade. However, its partial effectiveness means condoms remain essential.

The vaccine's 30–40% efficacy stems from its origin as a meningitis B vaccine, highlighting the innovative approach to combating antibiotic-resistant gonorrhoea.